Nanobiotix (5NRA) Financial Statements
Nanobiotix Financial Overview
Nanobiotix's market cap is currently $1.43B. The company's EPS TTM is $-1.10; its P/E ratio is -25.56; Nanobiotix is scheduled to report earnings on April 27, 2027, and the estimated EPS forecast is $0.05. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 29.64M | $ -7.19M | $ 36.21M | $ 4.78M | $ 2.65M |
| Gross Profit | $ 29.64M | $ -7.19M | $ 36.21M | $ 4.78M | $ 2.65M |
| Operating Income | $ -10.82M | $ -68.39M | $ -26.78M | $ -46.70M | $ -52.58M |
| EBITDA | $ -12.07M | $ -66.64M | $ -22.72M | $ -44.22M | $ -45.60M |
| Net Income | $ -23.96M | $ -68.13M | $ -39.70M | $ -57.04M | $ -47.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 52.75M | $ 49.74M | $ 75.28M | $ 41.39M | $ 84.17M |
| Total Assets | $ 67.76M | $ 67.42M | $ 93.90M | $ 59.77M | $ 101.77M |
| Total Debt | $ 95.32M | $ 50.90M | $ 50.56M | $ 53.17M | $ 46.02M |
| Net Debt | $ 42.57M | $ 1.17M | $ -24.72M | $ 11.78M | $ -37.90M |
| Total Liabilities | $ 152.24M | $ 133.12M | $ 95.74M | $ 86.81M | $ 74.98M |
| Stockholders' Equity | $ -84.48M | $ -65.70M | $ -1.84M | $ -27.05M | $ 26.79M |
| Cash Flow | |||||
| Free Cash Flow | $ -33.97M | $ -20.40M | $ -12.80M | $ -37.20M | $ -30.10M |
| Operating Cash Flow | $ -33.42M | $ -19.55M | $ -12.48M | $ -37.10M | $ -29.87M |
| Investing Cash Flow | $ -578.00K | $ -955.00K | $ -349.00K | $ 138.00K | $ -242.00K |
| Financing Cash Flow | $ 37.42M | $ -5.13M | $ 46.77M | $ -5.65M | $ -5.18M |
Currency in EUR